Cancer Vaccines

Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum

“…However, whole-cell-derived vaccines have a lower neoantigen presentation rate due to the abundant presence of non-mutated self-peptides, which might dilute the HLA presentation of the neoantigens. 41 Another limitation is the significant cost of manufacturing autologous monocyte-derived DCs according to GMP standards. Classically, antigen-loaded, autologous monocyte-derived DCs for clinical use are generated according to a 7- to 8-day culture protocol.…”